Nakamura et al. believed that the persistence of anti‐gp210 after UDCA treatment is a risk factor for the progression to end‐stage hepatic failure, whereas the disappearance of anti‐gp210 after therapy indicate a more favorable clinical course in PBC.37 This evidence concerns the gene NUP210 and primary biliary cholangitis.